RU2014131285A - Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения - Google Patents

Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения Download PDF

Info

Publication number
RU2014131285A
RU2014131285A RU2014131285A RU2014131285A RU2014131285A RU 2014131285 A RU2014131285 A RU 2014131285A RU 2014131285 A RU2014131285 A RU 2014131285A RU 2014131285 A RU2014131285 A RU 2014131285A RU 2014131285 A RU2014131285 A RU 2014131285A
Authority
RU
Russia
Prior art keywords
spp
vig
igufkvvp2
fkpp
sio
Prior art date
Application number
RU2014131285A
Other languages
English (en)
Other versions
RU2603471C2 (ru
Inventor
Дэвид А. ДИЛЛ
Original Assignee
УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/343,332 external-priority patent/US20120135050A1/en
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of RU2014131285A publication Critical patent/RU2014131285A/ru
Application granted granted Critical
Publication of RU2603471C2 publication Critical patent/RU2603471C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Guiding Agricultural Machines (AREA)
  • Power-Operated Mechanisms For Wings (AREA)

Abstract

1. Ссчм ввнвэиэкфк сагуфксввссзв игуавпвсдо1 мд2000 м2. Спп 1, гуавпвсдо50 мд1000 м3. Спп 1, гуавпвсдо500 мд2000 м4. Спп 1, гуавпвсдо100 мд1500 м5. Спп 1, гуавпвсдо250 мд1000 м6. Спп 1, гуфксввссзвпзуавмино ва.7. Спп 1, гуссзвсп квпкрв8. Спп 1, гуссзвсвинввп ом9. Спп 1, гуссзвпрвкп10. Спп 1, гуфкдса виг сиа и нн н иин гуавпвсдо50 мд2000 м11. Спп 10, гуавпвсдо100 мд1500 м12. Спп 10, гуавпвсдо250 мд1000 м13. Спп 1, гуфкдсас виг сио с диа14. Спп 1, гуфкдсоина15. Спп 1, гуфкдсонинс16. Спп 1, дввуидгудвпммз8 чдзв игуфкввп2 чдузв17. Ссчм ввнвэиэкфк спк сдбв ивк сдзвгупкиувкса игуавпвсдо50 мд2000 м18. Спп 17, гуфкпрвкп19. Спп 17, гупкииувкдсас виг сио с диа20. Спп 17, гупкииувкдса21. Спп 17, гупкииувкдсоинс22. Спп 17, дввуидгудвпммз8 чдзав игуфкввп2 чдузв23. Фк саа ифпнгуфксдзв игдасо50 мд2000 м24. Фкпп 23, дсас25. Фкпп 23, дсс

Claims (25)

1. Ссчм в
внвэиэкфк са
гуфксввссзв игуавпвсдо1 мд2000 м
2. Спп 1, гуавпвсдо50 мд1000 м
3. Спп 1, гуавпвсдо500 мд2000 м
4. Спп 1, гуавпвсдо100 мд1500 м
5. Спп 1, гуавпвсдо250 мд1000 м
6. Спп 1, гуфксввссзвпзуавмино ва.
7. Спп 1, гуссзвсп квпкрв
8. Спп 1, гуссзвсвинввп ом
9. Спп 1, гуссзвпрвкп
10. Спп 1, гуфкдса виг сиа и нн н иин гуавпвсдо50 мд2000 м
11. Спп 10, гуавпвсдо100 мд1500 м
12. Спп 10, гуавпвсдо250 мд1000 м
13. Спп 1, гуфкдсас виг сио с диа
14. Спп 1, гуфкдсоина
15. Спп 1, гуфкдсонинс
16. Спп 1, дв
вуид
гудвпммз8 чдзв игуфкввп2 чдузв
17. Ссчм в
внвэиэкфк с
пк сдбв и
вк сдзв
гупкиувкса игуавпвсдо50 мд2000 м
18. Спп 17, гуфкпрвкп
19. Спп 17, гупкииувкдсас виг сио с диа
20. Спп 17, гупкииувкдса
21. Спп 17, гупкииувкдсоинс
22. Спп 17, дв
вуид
гудвпммз8 чдзав игуфкввп2 чдузв
23. Фк с
а
а и
фпн
гуфксдзв игдасо50 мд2000 м
24. Фкпп 23, дсас
25. Фкпп 23, дсс
RU2014131285/15A 2012-01-04 2012-08-22 Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения RU2603471C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13/343,332 US20120135050A1 (en) 2010-07-08 2012-01-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/343,332 2012-01-04
US13/424,000 2012-03-19
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 2012-06-04
PCT/US2012/051888 WO2013103390A1 (en) 2012-01-04 2012-08-22 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (2)

Publication Number Publication Date
RU2014131285A true RU2014131285A (ru) 2016-02-20
RU2603471C2 RU2603471C2 (ru) 2016-11-27

Family

ID=48745355

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014131285/15A RU2603471C2 (ru) 2012-01-04 2012-08-22 Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения

Country Status (13)

Country Link
US (3) US8685453B2 (ru)
JP (4) JP2015503583A (ru)
KR (2) KR20180025993A (ru)
AU (2) AU2012363789B2 (ru)
BR (1) BR112014016661A8 (ru)
CA (1) CA2856677A1 (ru)
IL (1) IL232715A0 (ru)
MX (1) MX2014008283A (ru)
MY (1) MY173582A (ru)
RU (1) RU2603471C2 (ru)
SG (1) SG11201500407XA (ru)
WO (1) WO2013103390A1 (ru)
ZA (1) ZA201404606B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
JP6134316B2 (ja) 2011-07-18 2017-05-24 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法
CN106220546B (zh) * 2012-03-30 2018-11-30 奇华顿股份有限公司 作为食品加香化合物的n-酰基脯氨酸衍生物
WO2015187183A1 (en) * 2014-06-06 2015-12-10 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
RU2017113827A (ru) * 2014-09-24 2018-10-24 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтический состав для уменьшения спазмов мочевого пузыря и способ его применения
AU2016317092A1 (en) * 2015-09-01 2018-04-26 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
RU2018111401A (ru) * 2015-09-01 2019-10-02 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Составы с отсроченным высвобождением, способы их получения и применения
WO2017058436A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
JP7229012B2 (ja) * 2018-12-25 2023-02-27 小林製薬株式会社 内服用医薬組成物
JP2019069991A (ja) * 2018-12-27 2019-05-09 ウェルズリー ファーマスーティカルズ、エルエルシー 膀胱痙攣を低減するための医薬製剤およびその使用の方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100243956B1 (ko) * 1991-09-06 2000-03-02 랄프 알. 팔로 트라마돌 물질 및 아세트아미노펜을 포함하는 통증 치료용 약제학적 조성물
WO1998046216A1 (fr) * 1997-04-11 1998-10-22 Nippon Shinyaku Co., Ltd. Traitements des mictions frequentes et de l'incontinence urinaire
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
JP3660979B2 (ja) * 2000-09-05 2005-06-15 国立大学法人金沢大学 夜間頻尿症の治療剤、夜間頻尿症の予防剤
RU2193401C1 (ru) * 2001-04-02 2002-11-27 Аль-Шукри Салман Хасунович Способ лечения гиперактивности мочевого пузыря
EP1447096A1 (en) * 2001-11-19 2004-08-18 Ono Pharmaceutical Co., Ltd. Remedies for urinary frequency
MXPA04008037A (es) * 2002-02-19 2004-11-26 Pharmacia Corp Uso de inhibidores de la ciclooxigenasa y de agentes antimuscarinicos para el tratamiento de la incontinencia.
AU2003281044A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Pyrrolopyridine derivative and use thereof
KR100522239B1 (ko) * 2002-07-16 2005-10-18 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
WO2004026308A1 (fr) * 2002-09-21 2004-04-01 Shuyi Zhang Compose d'acetamidophenol et de tramadol a liberation prolongee
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DE10356112A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
WO2006059237A1 (en) * 2004-08-30 2006-06-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
EP1879578A4 (en) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
CA2603926A1 (en) * 2005-04-08 2006-10-12 Neuromed Pharmaceuticals Ltd. Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain
UA89684C2 (ru) * 2005-07-20 2010-02-25 Панасеа Биотек Лтд. Двухслойная фармацевтическая дозированная форма с модифицированным высвобождением нимесулида
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
US20070237816A1 (en) * 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief
WO2008014175A2 (en) 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
JP5345620B2 (ja) * 2007-08-15 2013-11-20 マクニール−ピーピーシー・インコーポレーテツド 即時放出及び徐放型イブプロフェンの投与法
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery

Also Published As

Publication number Publication date
NZ721818A (en) 2017-07-28
JP2020037575A (ja) 2020-03-12
NZ732149A (en) 2018-11-30
AU2012363789B2 (en) 2017-04-13
US20150272968A1 (en) 2015-10-01
MX2014008283A (es) 2015-03-03
KR20180025993A (ko) 2018-03-09
AU2017203418A1 (en) 2017-06-08
US20130216620A1 (en) 2013-08-22
AU2017203418B2 (en) 2019-01-17
CA2856677A1 (en) 2013-07-11
NZ626619A (en) 2017-03-31
WO2013103390A1 (en) 2013-07-11
BR112014016661A8 (pt) 2017-07-04
KR20140108675A (ko) 2014-09-12
US8685453B2 (en) 2014-04-01
MY173582A (en) 2020-02-04
RU2603471C2 (ru) 2016-11-27
IL232715A0 (en) 2014-07-31
ZA201404606B (en) 2015-11-25
JP2018087217A (ja) 2018-06-07
JP2015503583A (ja) 2015-02-02
BR112014016661A2 (pt) 2017-06-13
AU2012363789A1 (en) 2014-07-17
AU2012363789A2 (en) 2014-07-24
SG11201500407XA (en) 2015-03-30
US20140154320A1 (en) 2014-06-05
JP2017031172A (ja) 2017-02-09

Similar Documents

Publication Publication Date Title
RU2014131285A (ru) Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения
SG10201808967YA (en) Heterodimeric immunoglobulins
MX2015010427A (es) Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos.
CL2017002146A1 (es) Método para la reducción de la viscosidad de un anticuerpo en el que el anticuerpo comprende una región constante de la cadena pesada de subclase igg1 humana o igg4 humana (derivada de origen humano y) que comprende la modificación de la región constante de la cadena pesada del anticuerpo de subclase igg1 humana o igg4 humana con las mutaciones i253a, h310a, y h435a (divisional solicitud no. 61-2015).
EA201591671A1 (ru) Аэрированные композиционные материалы, способы их получения и применения
TWD160608S (zh) 遮陽簾之單元
EA201690405A1 (ru) Аэрированные композиционные материалы, способы их получения и применения
EA201591672A1 (ru) Железнодорожные шпалы из композиционных материалов и способы их получения и применения
TWD160278S (zh) 行動電話
SE0502829L (sv) Formattering av provisioneringsinnehåll i ett mobilt apparathanteringssystem
MX2015010429A (es) Cetuximab con glicosilación modificada y sus usos.
BR112015030685A2 (pt) método para diferenciar células-tronco, células, biobanco de células, uso das células e composição terapêutica
IN2014DN07958A (ru)
BR112015029599A2 (pt) tinturas ácidas, processo para a produção das mesmas e seu uso
IN2013MU02428A (ru)
CL2019003547A1 (es) Método de producción y recuperación de azufre en digestores anaerobios mediante la aplicación de microaieración y el uso de zeolitas naturales
Altın Nance A Holistic Approach to Ecological Living
Gromov Prospects for Intensifying and Spreading Creativity as a Precondition of Social Progress
Xiao et al. Analysis on the causes why the extensive growth mode exist for a long time in China
GB201905700D0 (en) The My Community App is an mobile app(application) build for people with in the community to help each other with the information
Xiaoke et al. Research on Laboratory Management Based on the Internet of Things
PL422357A1 (pl) Przenośny obiekt budowlany treningowy
UA87011U (ru) Способ прогнозирования изменений в водных экосистемах при воздействии естественных и антропогенных факторов путем использования микрокосмов с регистрационными камерами
González Exponential type integrators for abstract quasilinear parabolic equations with variable domains
Miyazaki et al. Craftsperson's Employment System for Porcelain in Jingdezhen Through a survey of handmade ceramic in Jingdezhen

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190823